The trio was honored on October 5, 2026, for their discovery of light-sensitive ion channels and the development of optogenetics, a technique that revolutionized the study of brain function.
Optogenetics: Controlling Neural Activity with Light
The 2026 prize recognizes a fundamental shift in neuroscience. By identifying proteins in algae that respond to light—specifically channelrhodopsins—the laureates enabled researchers to control the activity of specific neurons with unprecedented precision. This method, known as optogenetics, allows scientists to turn individual nerve cells on or off using light pulses, providing a level of control previously unattainable with traditional electrical stimulation.
The Research Contributions of Deisseroth, Hegemann, and Nagel
- Karl Deisseroth: Developed the application of light-responsive proteins within nerve cells, enabling the precise manipulation of neural circuits.
- Peter Hegemann: Played a lead role in discovering channelrhodopsin, the light-responsive protein found in algae that serves as the foundation for the technology.
- Georg Nagel: Contributed to the identification and study of the biological properties of these light-responsive proteins, confirming how they could be harnessed for cellular control.
Committee Reveals Winner After Fifty Years
The announcement, made in Stockholm on October 5, 2026, marks the conclusion of a selection process that remained confidential for 50 years, as per the committee’s standard practice.
Prior to the official selection, various institutions and publications released projections. Organizations like Clarivate, which annually lists researchers whose high citation counts suggest they are at a "Nobel level," and The Scientist, which polls researchers for their predictions, had highlighted other potential candidates. Similarly, Lotte Bjerre Knudsen, a Danish pharmacologist noted for her work on long-acting GLP-1 treatments for obesity and diabetes, was a prominent name in pre-award discussions. John Eng was also noted in scientific circles for his research on exendin-4, a compound derived from Gila monster venom that proved pivotal in developing early GLP-1 receptor agonists.
